Total apoB particle count and Lp(a) levels best reflect coronary artery disease risk, with researchers noting that lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P.
A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Mavacamten's phase III trial for nonobstructive hypertrophic cardiomyopathy does not show significant improvement in functional capacity or symptoms, reflecting challenges in less severe populations. Bristol Myers Squibb plans to present full data at a future scientific meeting.
In a registry-based study of 79,550 patients, tenecteplase showed comparable short-term safety and effectiveness to alteplase for acute ischemic stroke, with no significant differences in functional outcomes or hemorrhagic events.